Company: IXHL
Filing Date: 2025-04-28
Form Type: 424B3
Source: 0001213900-25-036065
Chunk: 24

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-28
Form: 424B3
Chunk 24
---
) and
number of shares underlying the Series A Warrants (from 11,574,090 to up to 115,740,900, assuming full adjustment of the exercise price
to the Floor Price and before giving effect to the zero exercise price provision and 347,222,700 assuming full adjustment of the exercise
price and giving effect to the zero exercise price provision) as discussed above in the section entitled “Prospectus Summary-the
2025 Private Placement”.

<div align='center'>8

SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION</div>

This prospectus, including
documents incorporated by reference herein and therein, and any free writing prospectus that we have authorized for use in connection
with this offering, contain forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the
Exchange Act. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or our
future performance, and they are based on our current assumptions, expectations and beliefs concerning future developments and their potential
effect on our business. The words “believe,” “may,” “will,” “potentially,” “estimate,”
“continue,” “anticipate,” “intend,” “could,” “would,” “project,”
“plan,” “expect,” “possible,” “likely,” “probable,” and similar expressions
that convey uncertainty of future events or outcomes identify forward-looking statements. These statements include, among other things,
statements regarding:

| ● | our ability to implement our product development and business strategies, including our ability to continue                       
 to pursue development pathways and regulatory strategies for IHL-42X, PSX-001, and IHL-675A and any of our other drug candidates; |

| ● | estimates regarding market size and related future growth rates; |

| ● | our research and development activities, including clinical testing and manufacturing and the related 
 costs and timing;                                                                                     |

| ● | the possibility that we may be required to conduct additional clinical studies or trials for our drug 
 candidates and the consequences resulting from the delay in obtaining necessary regulatory approvals; |

| ● | the timing, scope or likelihood of regulatory filings and approvals and our ability to obtain and maintain 
 regulatory approvals for our drug candidates for any indication;                                           |

| ● | the pricing, coverage and reimbursement of our drug candidates, if approved and commercialized; |

| ● | the rate and degree of market acceptance and clinical utility of our drug candidates; |